Review Paraoxonase-1 as a Regulator of Glucose and Lipid Homeostasis: Impact on the Onset and Progression of Metabolic Disorders Maria João Meneses 1,2, Regina Silvestre 1,3, Inês Sousa-Lima 1,4 and Maria Paula Macedo 1,4,5,* 1 CEDOC—Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, 1150-082 Lisbon, Portugal 2 ProRegeM PhD Programme, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, 1150-082 Lisbon, Portugal 3 Faculdade de Ciências e Tecnologias, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal 4 APDP Diabetes Portugal–Education and Research Center (APDP-ERC), 1250-203 Lisbon, Portugal 5 Medical Sciences Department and iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal * Correspondence:
[email protected] Received: 29 July 2019; Accepted: 16 August 2019; Published: 19 August 2019 Abstract: Metabolic disorders are characterized by an overall state of inflammation and oxidative stress, which highlight the importance of a functional antioxidant system and normal activity of some endogenous enzymes, namely paraoxonase-1 (PON1). PON1 is an antioxidant and anti- inflammatory glycoprotein from the paraoxonases family. It is mainly expressed in the liver and secreted to the bloodstream, where it binds to HDL. Although it was first discovered due to its ability to hydrolyze paraoxon, it is now known to have an antiatherogenic role. Recent studies have shown that PON1 plays a protective role in other diseases that are associated with inflammation and oxidative stress, such as Type 1 and Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.